Portal de Periódicos da CAPES

Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance From Mayo Clinic

2020; Elsevier BV; Volume: 95; Issue: 11 Linguagem: Inglês

10.1016/j.mayocp.2020.08.030

1942-5546

Robert D. McBane, Victor D. Torres Roldan, Alexander S. Niven, Rajiv K. Pruthi, Pablo Moreno Franco, Jane A. Linderbaum, Ana I. Casanegra, Lance J. Oyen, Damon E. Houghton, Ariela L. Marshall, Narith N. Ou, Jason Siegel, Waldemar E. Wysokiński, Leslie Padrnos, Candido E. Rivera, Gayle L. Flo, Fadi Shamoun, Scott M. Silvers, Tarek Nayfeh, Meritxell Urtecho, Sahrish Shah, Raed Benkhadra, Samer Saadi, Mohammed Firwana, Tabinda Jawaid, Mustapha Amin, Larry J. Prokop, M. Hassan Murad,

Dermatological and COVID-19 studies

A higher risk of thrombosis has been described as a prominent feature of coronavirus disease 2019 (COVID-19). This systematic review synthesizes current data on thrombosis risk, prognostic implications, and anticoagulation effects in COVID-19. We included 37 studies from 4070 unique citations. Meta-analysis was performed when feasible. Coagulopathy and thrombotic events were frequent among patients with COVID-19 and further increased in those with more severe forms of the disease. We also present guidance on the prevention and management of thrombosis from a multidisciplinary panel of specialists from Mayo Clinic. The current certainty of evidence is generally very low and continues to evolve.